<br>        Inclusion Criteria:<br><br>          -  Established diagnosis of ulcerative colitis<br><br>          -  Active ulcerative colitis disease extent = 15 cm<br><br>          -  Active disease despite treatment with mesalamine<br><br>        Exclusion Criteria:<br><br>          -  Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis,<br>             microscopic colitis, diverticular disease associated colitis,<br><br>          -  Toxic megacolon or fulminant colitis<br><br>          -  Colon resection<br><br>          -  Evidence of infectious colitis<br><br>          -  Celiac disease<br><br>          -  Bleeding hemorrhoids<br><br>          -  History or presence of ischemic heart disease, myocardial infarction, peripheral<br>             arterial disease, ischemic stroke, or transient ischemic attack<br><br>          -  Any severe concomitant renal, endocrine, or psychiatric disorder<br><br>          -  Any relevant known systemic disease<br><br>          -  History of cancer in the last five years<br><br>          -  Abnormal hepatic function or liver cirrhosis<br><br>          -  Abnormal HbA1c at screening visit<br><br>          -  Patients with known hypersensitivity to soy<br><br>          -  Known intolerance/hypersensitivity to Investigational Medicinal Product (IMP)<br><br>          -  Treatment with steroids/methotrexate/Tumor necrosis<br>             factor-alpha-antagonists/azathioprine/ 6-mercaptopurine/anti-integrin/coumarins<br><br>          -  Treatment with other investigational drug<br><br>          -  Existing or intended pregnancy or breast-feeding<br>      ;<br>        Inclusion Criteria:<br><br>          -  Established diagnosis of ulcerative colitis<br><br>          -  Active ulcerative colitis disease extent = 15 cm<br><br>          -  Active disease despite treatment with mesalamine<br><br>        Exclusion Criteria:<br><br>          -  Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis,<br>             microscopic colitis, diverticular disease associated colitis,<br><br>          -  Toxic megacolon or fulminant colitis<br><br>          -  Colon resection<br><br>          -  Evidence of infectious colitis<br><br>          -  Celiac disease<br><br>          -  Bleeding hemorrhoids<br><br>          -  History or presence of ischemic heart disease, myocardial infarction, peripheral<br>             arterial disease, ischemic stroke, or transient ischemic attack<br><br>          -  Any severe concomitant renal, endocrine, or psychiatric disorder<br><br>          -  Any relevant known systemic disease<br><br>          -  History of cancer in the last five years<br><br>          -  Abnormal hepatic function or liver cirrhosis<br><br>          -  Abnormal HbA1c at screening visit<br><br>          -  Patients with known hypersensitivity to soy<br><br>          -  Known intolerance/hypersensitivity to Investigational Medicinal Product (IMP)<br><br>          -  Treatment with steroids/methotrexate/Tumor necrosis<br>             factor-alpha-antagonists/azathioprine/ 6-mercaptopurine/anti-integrin/coumarins<br><br>          -  Treatment with other investigational drug<br><br>          -  Existing or intended pregnancy or breast-feeding<br>      ;<br>        Inclusion Criteria:<br><br>          -  Established diagnosis of ulcerative colitis<br><br>          -  Active ulcerative colitis disease extent = 15 cm<br><br>          -  Active disease despite treatment with mesalamine<br><br>        Exclusion Criteria:<br><br>          -  Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis,<br>             microscopic colitis, diverticular disease associated colitis,<br><br>          -  Toxic megacolon or fulminant colitis<br><br>          -  Colon resection<br><br>          -  Evidence of infectious colitis<br><br>          -  Celiac disease<br><br>          -  Bleeding hemorrhoids<br><br>          -  History or presence of ischemic heart disease, myocardial infarction, peripheral<br>             arterial disease, ischemic stroke, or transient ischemic attack<br><br>          -  Any severe concomitant renal, endocrine, or psychiatric disorder<br><br>          -  Any relevant known systemic disease<br><br>          -  History of cancer in the last five years<br><br>          -  Abnormal hepatic function or liver cirrhosis<br><br>          -  Abnormal HbA1c at screening visit<br><br>          -  Patients with known hypersensitivity to soy<br><br>          -  Known intolerance/hypersensitivity to Investigational Medicinal Product (IMP)<br><br>          -  Treatment with steroids/methotrexate/Tumor necrosis<br>             factor-alpha-antagonists/azathioprine/ 6-mercaptopurine/anti-integrin/coumarins<br><br>          -  Treatment with other investigational drug<br><br>          -  Existing or intended pregnancy or breast-feeding<br>      ;<br>        Inclusion Criteria:<br><br>          -  Established diagnosis of ulcerative colitis<br><br>          -  Active ulcerative colitis disease extent = 15 cm<br><br>          -  Active disease despite treatment with mesalamine<br><br>        Exclusion Criteria:<br><br>          -  Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis,<br>             microscopic colitis, diverticular disease associated colitis,<br><br>          -  Toxic megacolon or fulminant colitis<br><br>          -  Colon resection<br><br>          -  Evidence of infectious colitis<br><br>          -  Celiac disease<br><br>          -  Bleeding hemorrhoids<br><br>          -  History or presence of ischemic heart disease, myocardial infarction, peripheral<br>             arterial disease, ischemic stroke, or transient ischemic attack<br><br>          -  Any severe concomitant renal, endocrine, or psychiatric disorder<br><br>          -  Any relevant known systemic disease<br><br>          -  History of cancer in the last five years<br><br>          -  Abnormal hepatic function or liver cirrhosis<br><br>          -  Abnormal HbA1c at screening visit<br><br>          -  Patients with known hypersensitivity to soy<br><br>          -  Known intolerance/hypersensitivity to Investigational Medicinal Product (IMP)<br><br>          -  Treatment with steroids/methotrexate/Tumor necrosis<br>             factor-alpha-antagonists/azathioprine/ 6-mercaptopurine/anti-integrin/coumarins<br><br>          -  Treatment with other investigational drug<br><br>          -  Existing or intended pregnancy or breast-feeding<br>